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Abstract Atrial fibrillation is a commonly encountered pathology in medical practice, and its 
prevalence has shown a continuous rise over the past years. Atrial fibrillation has a 
significant impact on patients' quality of life, not only due to the standard anticoagulant 
treatment with vitamin K antagonists that require close monitoring and dose adjustment, 
but also due to the fragile equilibrium between hemorrhagic and thrombotic risks. The 
introduction of new oral anticoagulants (NOACs) in the treatment guidelines for atrial 
fibrillation has improved the quality of life, as NOACs do not require close monitoring 
or dose adjustments. However, even if the safety profile of the NOACs regarding the 
hemorrhagic risk is superior to vitamin K antagonists, the problem raised by an 
unexpected hemorrhage (e.g. severe hemorrhage after an accident) and the need for 
efficient hemostasis in a chronic anticoagulated patient has remained unsolved. To find 
a solution for this problem, reversal agents for NOACs have been developed and tested, 
and two of them, idarucizumab and andexanet-alpha, have already been approved by the 
FDA, thus making NOACs increasingly appealing as a choice of anticoagulation 
treatment.    
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Highlights ✓ Long-term oral anticoagulant therapy includes vitamin K antagonists and new oral 
anticoagulants (NOACs). 
✓ The introduction of NOACs in the treatment guidelines for atrial fibrillation has improved 
the quality of life of patients, as they do not require close monitoring or dose adjustments.   
✓ NOACs are divided into two broad categories, depending on the mechanism of action: 
substances that directly inhibit the activity of thrombin (e.g. dabigatran) and substances 
that directly inhibit activated factor X (e.g. rivaroxaban, apixaban, edoxaban).   
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Introduction    
Atrial fibrillation – epidemiological data    
Atrial fibrillation is a frequent pathology in medical 
practice, which despite treatment and careful 
management, remains the primary cause of heart failure, 
stroke, and even sudden death (1-3).  
Epidemiological data show a rise in the prevalence 
and incidence of this pathology (1). This could be due to 
easier detection of atrial fibrillation, access to ECG 
devices, and the possibility of ECG-Holter monitoring, 
thus discovering paroxysmal atrial fibrillation episodes 
otherwise undiagnosed.  
Global life expectancy has grown significantly 
between the years 1970 and 2015 (4), in some countries 
even up to 20 years, with average life expectancy around 
80 years at the European level (5). This implies a global 
increase in the prevalence of the elderly population, as 
well as of the chronic diseases associated with ageing, 
that increase the risk of developing atrial fibrillation 
(e.g. hypertension, ischemic heart disease, valvular 
diseases, etc.). Atrial fibrillation in Europe is estimated 
at 3% in adults older than 20 years, with an expected 
number of 14-17 million patients by 2030 in the 
European Union (6-8).   
Anticoagulant medication in patients with atrial 
fibrillation    
A major complication of atrial fibrillation is the 
increased risk of stroke. An essential objective in the 
treatment of atrial fibrillation is the prevention of stroke 
by using oral anticoagulant therapy (9). Long-term oral 
anticoagulant therapy includes vitamin K antagonists 
and new oral anticoagulants that should be personalized 
for each patient according to comorbidities in order to 
achieve a balance between thrombotic and hemorrhagic 
risk (10). 
The decision to anticoagulate a patient should take 
into consideration two scores for the assessment of 
thrombotic risk and hemorrhagic risk (9). 
The CHA2DS2-VASC score evaluates the risk of 
stroke in patients with non-valvular atrial fibrillation. 
CHA2DS2-VASC is calculated adding the points 
according to the presence of some major risk factors for 
stroke (Table 1). Anticoagulation therapy should be 
reconsidered in patients with a CHA2DS2-VASC score 
≥ 1 and is indicated at a score ≥ 2 (11, 12).    
 
Table 1. CHA2DS2-VASC score 
Points CHA2DS2-VASC 
1 Congestive heart failure 
1 Hypertension 
2 Age ≥ 75 years 
1 Diabetes mellitus 
2 
Stroke/ Transient Ischemic Attack/ 
Thromboembolic event 
1 
Vascular disease (prior Myocardial 
Infarction, Peripheric Arterial Disease 
or Aortic Plaque) 
1 Age 65 to 74 years 
1 Sex category (female sex)     
The HAS-BLED (Table 2) score assesses 
hemorrhagic risk. A high score is not a contraindication 
for anticoagulant treatment, but rather indicates the need 
for accurate detection and subsequent removal of the 
modifiable hemorrhagic risk factors. Modifiable 
hemorrhagic risk factors are uncontrolled arterial 
hypertension (especially a systolic blood pressure > 160 
mmHg), a labile INR or a therapeutic INR in less than 
60% of the time, usage of medication that predisposes to 
bleeding, or excess alcohol usage (13, 14). 
Table 2. HAS-BLED score.    
Points HAS-BLED 
1 
Hypertension (uncontrolled, systolic 
blood pressure >160 mmHg) 
1 Abnormal renal function 
1 Abnormal liver function 
1 Stroke 
1 Bleeding 
1 Labile INR 
1 Age > 65 years 
1 
Prior alcohol (≥ 8 drinks/week) or drug 
usage history 
1 
Medication usage predisposing to 
bleeding (antiplatelet agents, NSAIDs) 
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Discussions 
According to the latest European Society of 
Cardiology guideline, oral anticoagulant therapy is 
recommended only in non-valvular atrial fibrillation and 
is not recommended in patients with valvular atrial 
fibrillation (atrial fibrillation in patients with mitral 
stenosis or prosthetic valve) (8). In deciding the 
anticoagulant treatment, the comorbidities of the patient 
play a very important role (15-17).  
New oral anticoagulants    
These molecules have been developed because of 
the multiple disadvantages of vitamin K antagonists. 
Vitamin K antagonists (warfarin, acenocoumarol) have 
a long duration of action, with a long half-life and an 
unpredictable anticoagulant effect that requires careful 
and constant monitoring by checking the value of INR 
and adjusting doses accordingly. New oral 
anticoagulants have been synthesized as a higher-safety 
therapeutic option. These are divided into two broad 
categories, depending on the mechanism of action: 
substances that directly inhibit the activity of thrombin 
(e.g. dabigatran) and substances that directly inhibit 
activated factor X (e.g. rivaroxaban, apixaban, 
edoxaban). These new classes of anticoagulants have the 
advantage of a more predictable anticoagulant effect, 
fixed doses, and not requiring INR monitoring. In 
addition, studies have demonstrated the superior safety 
profile of the new anticoagulants compared to warfarin 
in the case of non-valvular atrial fibrillation (18). 
NOACs offer a superior safety profile compared with 
cumarinic anticoagulants in patients who need surgical 
interventions, with a shorter presurgery interrupting 
period. 
Dabigatran, the first approved NOAC, was 
introduced following the results of the RE-LY study 
(18). The dose of dabigatran is 110 mg twice daily or 
150 mg twice daily, the study demonstrating that both 
doses are non-inferior to warfarin. Compared to 
warfarin, dabigatran 110 mg, administered twice daily, 
demonstrated a lower rate of major hemorrhage, with 
similar per cent of stroke or systemic embolism (18). 
Administered 150 mg twice daily, dabigatran had 
similar major bleeding rates to warfarin, but lower rates 
of stroke or systemic embolism (18). The daily dose of 
dabigatran depends on the age and comorbidities of the 
patient. Treatment with dabigatran has been associated 
with a higher rate of digestive hemorrhage and dyspeptic 
symptoms. A possible explanation may be the tartaric 
acid, a component of the capsule, which is intended to 
provide a lower pH and better absorption at the digestive 
level (18). Dabigatran has predominantly renal 
elimination (80%); it is not recommended in patients 
with a creatinine clearance (CrCl) between 30-59 
mL/min and is contraindicated in patients with CrCl less 
than 30mL/min (19, 20).  
Rivaroxaban, according to the ROCKET-AF study, 
is also non-inferior to warfarin, with similar rates of 
stroke and systemic embolism prevention and of 
hemorrhagic risk (21). However, in the group of patients 
treated with rivaroxaban, a lower incidence of 
intracranial hemorrhage was observed and a greater 
frequency of digestive hemorrhage. The usual dose of 
rivaroxaban is a single dose of 20 mg per day or 10 
mg/day for patients with a CrCl of 15-49 mL/min (21, 
22). 
Apixaban has been shown in the ARISTOTLE 
study to be superior to warfarin regarding stroke 
prevention (18). Compared to warfarin, apixaban had 
lower rates of bleeding of any type, both intracranial 
hemorrhages and gastrointestinal bleeding, and is the 
only NOAC that shows significantly lower rates of all 
types of bleeding (23). Also, the group of patients 
treated with apixaban had a lower incidence of 
myocardial infarction than the group treated with 
warfarin. This result could be an advantage of apixaban 
compared to dabigatran, which had a higher incidence 
of myocardial infarction compared to the warfarin-
treated group. The standard dose of apixaban is 5 mg 
twice daily, apixaban being the NOAC with the lowest 
percentage of renal elimination (25%) (23). A lower 
dose to 2.5 mg twice daily is recommended if at least 
two of the three criteria are present: age > 80 years, 
weight < 60 kg or serum creatinine > 1.5 mg/dL (24). 
The latest NOAC is edoxaban, which was 
compared to warfarin in the ENGAGE-AF-TIMI study 
(25). Edoxaban has two dose regimens: high (a single 
daily dose of 60 mg) or low (a single daily dose of 30 
mg). Edoxaban proved to be non-inferior to warfarin 
regarding the prevention of ischemic stroke and 
systemic emboli, with a higher incidence of ischemic 
stroke when taken in a low-dose regimen, and a lower 
incidence when taken in the high-dose regimen (25). 
Both dose regimens demonstrate a significant decrease 
in bleeding complications, both intracranial 
hemorrhages and fatal hemorrhages, the only exception 
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being gastrointestinal hemorrhages that have a higher 
frequency only in the high-dose regimen group (25). An 
important drug interaction occurs with glycoprotein P 
inhibitors, such as verapamil or quinidine, so, in case of 
concomitant medication with these drugs, the dose of 
edoxaban should be reduced by half. Edoxaban is not 
recommended in patients with CrCl <30 mL/min. Doses 
should be adjusted for patients with a CrCl between 15-
49 mL/min, at 30 or 15 mg per day (25, 26). 
All NOACs have demonstrated a superior safety 
profile or at least non-inferior to warfarin regarding 
hemorrhagic risk, and are at least non-inferior to 
warfarin in the prevention of ischemic stroke and 
systemic embolism. However, the frequency of 
digestive hemorrhage was higher in patients treated with 
dabigatran, rivaroxaban, or edoxaban compared to 
patients treated with warfarin, apixaban being the 
NOAC with the lowest frequency of all types of 
hemorrhage, including gastrointestinal bleedings (27).  
The NOACs are not recommended in patients with 
severe renal dysfunction. A major drawback has been, 
until recently, the lack of an antidote, with the 
impossibility of stopping the anticoagulant effect in case 
of severely fatal bleeding (for example following severe 
trauma, the need of an emergency or urgent operation, 
etc.) (28, 29). Numerous surgical interventions, 
especially pelvic surgery, in both men and women, even 
not major, are associated with intraoperative blood 
losses (30). Elimination of NOACs is realized at the 
renal level, so kidney function must be carefully 
monitored during treatment with NOACs by monitoring 
the serum creatinine, both preoperative and 
postoperative (31).  
New perspectives in the acute treatment of 
hemorrhage in patients taking NOACs: reversal agents 
Idarucizumab and Andexanet Alpha 
To counter the anticoagulant effects of NOACs in 
case of acute bleeding, the reversal agents idarucizumab 
and andexanet alpha were recently introduced on the 
market.   
Idarucizumab is a monoclonal antibody that acts 
against dabigatran and was introduced on the market 
following the results of a REVERSE-AD study (32). 
Idarucizumab is given in a total dose of 5 g, divided into 
two 50 mL bolus infusions, over 10-15 minutes. Its 
effect is fast, the median time to reversing the effect 
being 2.5 hours (33). Idarucizumab has been approved 
in Europe and is indicated in life-threatening bleedings 
or emergency surgery, in patients with chronic 
anticoagulant therapy with dabigatran (34).   
In patients receiving preprocedural idarucizumab, 
efficient periprocedural hemostasis was obtained in 
93.4% of the cases (33). In addition, administration of 
idarucizumab does not expose to an additional 
procoagulant post-administration risk, the risk 
depending on the pre-existing risk factors of each 
patient. Only 4.8% of patients had thrombotic events 
within 30 days after idarucizumab administration (33). 
Idarucizumab can be administered regardless of the 
renal function, without the need for dose adjustment. 
One drawback is the lack of data regarding the use of 
idarucizumab in patients younger than 18 years old and 
in pregnant women.  
Also, immunogenic reactions may occur after 
administration of idarucizumab. So far, no allergic 
reactions to idarucizumab have been reported, but some 
cases of immunogenic reactions with anti-idarucizumab 
antibodies production have been reported, without 
affecting the response in case of a future administration 
(34). However, the data regarding these situations is 
limited and remains the subject of future studies. 
Andexanet Alfa is a recombinant modified human 
factor Xa molecule and is the second reversal molecule, 
recently approved by the FDA, against rivaroxaban and 
apixaban. According to the Andexanet-Alfa 4 study, it 
demonstrated its efficacy on both rivaroxaban and 
apixaban, without significant adverse effects (35). 
Andexanet Alfa was administered depending on the last 
dose of anticoagulant taken by the patient: if the last 
dose was administered more than 7 hours before, then 
400 mg of Andexanet Alfa had been given as a bolus, 
followed by 480 mg during 2 hours infusion. If the last 
dose of anticoagulant was taken less than 7 hours or if 
the last dose was unknown, then 800 mg of Andexanet 
Alfa had been given as a bolus, followed by 960 mg 
during 2 hours infusion (35). Effective hemostasis was 
reached 12 hours after infusion with Andexanet Alfa, 
being present in 79% of the study population. At 30 days 
post-administration, thrombotic events occurred in 18% 
of patients, and the mortality rate was 15% (35).   
Ciraparantag is a new reversing agent, which is the 
subject of the currently undergoing study "Phase 2 
Placebo-Controlled, Single-Site, Single-Blind Study of 
Rivaroxaban Reversal by Ciraparantag as Measured by 
WBCT" (36). Ciraparantag is a water-soluble molecule 
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that binds heparin and direct factor Xa and IIa inhibitors, 
which had promising results in phase I studies, 
managing to reverse anticoagulation due to edoxaban 
after a dose of 100-300 mg (36). 
Conclusions 
NOACs have entered the clinical practice, being 
recommended by international guidelines, 
demonstrating their efficacy and superior safety profile 
compared to warfarin. The emergence and approval of 
the new molecules, idarucizumab and andexanet alfa, 
solve one of the most important drawbacks of NOACs, 
the absence of a reversal agent, and provides the 
opportunity for better control of life-threatening 
bleedings or uncontrollable hemorrhages in emergency 
surgeries, for patients who follow chronic treatment 
with NOACs (37, 38).  
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